Media Release

Basel, 7 May 2003

Management Change in Roche’s Corporate Executive Committee

Daniel Villiger, member of Roche’s Corporate Executive Committee, and head of Corporate Services has decided to resign from his responsibilities as of July 1 2003 to pursue personal interests. His successor will be Gottlieb Keller, Roche’s Corporate Compliance Officer and Secretary to the Board of Directors.

Effective July 1 2003, Gottlieb Keller will join Roche’s Corporate Executive Committee and take over Corporate Human Resources and Pharma Site Management Basel and Kaiseraugust, in addition to his existing responsibilities. Corporate Communications will report to the CEO.

Dr. sc. pol. Daniel Villiger who joined Roche in 1999 has significantly strengthened Corporate Human Resources introducing new policies and programs in the areas of management development, international assignments and employee stock programs (Roche Connect). In addition, since 2000 Daniel Villiger has been responsible for the site services in Basel and Kaiseraugst.

Dr. iur. Gottlieb Keller began his career at Roche 1984 in Corporate Law. From 1989 onwards he held various positions in Pharma Marketing in Grenzach, Germany. From 1992 to 1995 he was Assistant to the Chairman. In 1996 he took over responsibility for Human Resources Roche Grenzach and became Chairman of the Executive Board of Roche Deutschland Holding GmbH before being promoted to his current position in 1999.

Headquartered in Basel, Switzerland, Roche is one of the world’s leading innovation-driven healthcare groups. Its core businesses are pharmaceuticals and diagnostics. Roche is number one in the global diagnostics market, the leading supplier of pharmaceuticals for cancer and a leader in virology and transplantation. As a supplier of products and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche employs roughly 62,000 people in 150 countries. The Group has alliances and research and development agreements with numerous partners, including majority ownership interests in Genentech and Chugai.

Further Information
- CV and photo of Gottlieb Keller